Apple says new CareKit platform will ‘empower’ Parkinson’s patients
Author: Geoffrey ChangPublished: 24 March 2016
Prep: Cook: Serves:
People with Parkinson’s will be among the first to experience the benefits of Apple’s new open-source health-tracking platform, which will ‘empower’ patients – and could transform the way we think about health
Apple has revealed a new health-tracking software platform at its ‘Loop You In’ product launch event. CareKit is a software framework designed for apps that let people with Parkinson’s and other chronic diseases better understand and manage their condition.
With the introduction of the platform, Apple aims to put patients back in charge of tracking symptoms and medications with the use of a smartphone.
Though CareKit won’t be fully available until next month, one of the apps to have first access to the platform is for people with Parkinson’s, and will monitor the effectiveness of medication used to treat the condition.
Jeff Williams, Chief Operating Officer of Apple, said: “We believe that giving individuals the tools to understand what is happening with their health is incredibly powerful. Apps designed using CareKit make this a reality by empowering people to take a more active role in their care.”
After the success of ResearchKit, the study-focused platform that enabled medical researchers to gather highly individualised data on a large-scale, Apple decided to widen the scope from medical research to personal care with the development of CareKit.
Developed by Sage Bionetworks and the University of Rochester, the first app built for ResearchKit was mPower, which claims to be responsible for the biggest Parkinson’s study to date.
Dr Stephen Friend, president of Sage Bionetworks, said: “mPower allows researchers to follow day-to-day fluctuations in Parkinson’s disease symptoms and allows for insights that would be impossible to achieve when a patient is only being examined every six months.
“This kind of data has never been tracked and captured before, and now with the help of CareKit, we can provide quantitative insights to inform the dialogue a person has with a health professional about his or her own disease.”
CareKit will be available in April. For more information click here
How CareKit could benefit people with Parkinson’s
Apps built for CareKit will be able to utilise specialised ‘modules’ such as the so-called ‘Care Card’, ‘Insight Dashboard’, ‘Symptoms and Measurement tracker’ and ‘Connect’.
Here’s how the modules could work with Parkinson’s apps:
‘Care Card’ keeps tabs on your medication or physical therapy needs, essentially creating interactive to-do lists that remind you when to take your medicine.
‘Insight Dashboard’ maps progress over time and can reveal which treatments are actually working in relation to symptom fluctuation.
‘Symptoms and Measurement tracker’takes advantage of the iPhone’s high-tech sensory capabilities such as accelerometers, microphones, gyroscopes, cameras and GPS. For example, the phone’s microphone can record and analyse the subtle changes in the voice of Parkinson’s patients, or the gyroscope and accelerometers can sense a range of motions like fluctuations in gait.
‘Connect’ allows all this information to be shared with doctors, healthcare teams and family members.
Journalist Liz Jackson’s emotional film about her Parkinson’s is “TV at its finest”
An outpouring of sympathy for award-winning journalist
8 months ago
35 new Parkinson’s drug trials launched in last year
Researchers launched 35 new clinical trials of Parkinson’s drug therapies in the last year, according to recent findings published in the ‘Journal of Parkinson’s Disease’. The 2023 Parkinson’s drug development pipeline report noted a slight decrease in active trials compared to the 2022 update (down from 147 to 139 overall). About one-third of trials were still in Phase 1, half were in Phase 2 – and just 20 (14%) were in Phase 3, raising concerns about ‘slow progress’. However, of the active trials logged on ClinicalTrials.gov at the time of the latest report, 35 were found to be newly registered. The report authors concluded: “The slow progress and lack of agents transitioning from Phase 2 to Phase 3 is concerning, but collective efforts by various stakeholders are being made to accelerate the clinical trial process, with the aim of bringing new therapies to the [Parkinson’s] community sooner.”
Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award
Parkinson’s Europe co-founder Lizzie Graham has won a World Parkinson Coalition (WPC) award for her contribution to the Parkinson’s community. Lizzie is one of four people set to receive the Robin Elliott Award – which is given out every three years to individuals whose efforts best embody the goals and ethos of the WPC. She will be presented with the award in a ceremony at the World Parkinson’s Congress, which will be held in Barcelona later this year. Commenting on the news of Lizzie’s award, Parkinson’s Europe President, Veronica Clark, said: “Lizzie is Lizzie, and we love her for who she is and what she has done for us all – for people with Parkinson’s past and present and, I’m sure, future.” Lizzie co-founded the European Parkinson’s Disease Association (renamed Parkinson’s Europe last year) in 1992. She has since held several roles within the organisation – including secretary general and…
Study explores predictors of cognitive impairment in Parkinson’s disease
Cognitive impairment can affect some people with Parkinson’s – and may greatly impact their quality of life. Now, researchers in China have examined the possible risk factors for cognitive impairment in those with the condition. The study analysed data from 409 people with Parkinson’s within two years of their involvement in the Parkinson’s Progression Markers Initiative (PPMI) – an international study that follows people with and without the condition over time. The participants, who were newly diagnosed and experiencing normal cognitive function at the start of the research, were studied for at least five years. Published in ‘Frontiers in Aging Neuroscience’, the results indicate that older age at onset, high blood pressure and worse baseline motor symptoms may be among factors that could contribute to an increased risk of developing cognitive impairment. The researchers cautioned that “a larger sample and much more comprehensive assessment, and prolonged follow-up, will be required”.